… of the effectiveness of a monoclonal antibody in an infectious disease in humans. Monthly …
of palivizumab reduced the incidence of hospitalization because of a RSV infection compared …

… Approximately two-thirds of infants are infected with RSV … ), a humanized RSV neutralizing
monoclonal antibody, received … lower respiratory infection in pediatric patients at high risk for …

… antibody (Mab), has been licensed in 1998 for prophylactic use to prevent RSV associated
hospitalizations in high-risk infants. … in reducing RSV hospitalization rates in high-risk infants.…

… , as well as prematurely born infants without CLD experienced a reduced number of … of
RSV infections in high-risk infants. Palivizumab is a humanized monoclonal antibody directed …

… humanized monoclonal antibody on June 19, 1998, establishing palivizumab as the first
monoclonal antibody … with palivizumab should significantly reduce RSV hospitalization rates in …

… immunity with the monoclonal antibody palivizumab is the … Palivizumab is a humanized
monoclonal antibody specific for … Since approval in 1998, palivizumab has been used in more …

… high risk infants and children who received prophylaxis for RSV, the risk factors for RSV …
lower respiratory tract infection (Table 4). Since 1998 programs giving palivizumab to high risk …

… Palivizumab, a humanized monoclonal antibody, was … in the prevention of RSV infection in
high risk preterm infants. … population of infants hospitalized with respiratory infections (1998 to …

… lower respiratory tract infection in infants. MEDI-493(palivizumab) is a humanized monoclonal
antibody … days to pediatric patients at high risk for serious RSV disease. Monthly doses of …

… Palivizumab, a humanized monoclonal antibody against the RSV F protein, is the only …
In 1998, the FDA approved the use of palivizumab for RSV prophylaxis in high-risk children. …